Joshua Brody, Director of Lymphoma Immunotherapy Program at The Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Practice-changing ASH24 updates on Follicular Lymphoma immunotherapy including earlier rx with bispecific Abs and novel combinations from trials and around the world!”
Further Reading: